Post-authorisation safety study (PASS): observational cohort study of PAH patients newly treated with either UPTRAVI (selexipag) or any other PAH-specific therapy, in clinical practice (EXPOSURE)

ENCePP Code of conduct

No

Data sources

• Data source(s):
  Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension
• Data sources (types):
  Disease registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No